TABLE 2

Percentages of women who have antibodies to the antigens (seropositivity)a

Antigen% of all women (n = 1,342)% of PM+ women% of PM− womenCMH P valuec
All (n = 328)G1 (n = 117)G2 (n = 73)G3 (n = 45)G4+ (n = 93)P valuebAll (n = 1,014)G1 (n = 244)G2 (n = 216)G3 (n = 175)G4+ (n = 379)P valueb
FV238.656.147.043.864.473.1<0.000132.917.631.932.043.8<0.0001<0.0001
MSP14262.373.869.268.575.682.80.02058.852.556.560.662.80.00760.0075
MSP274.787.588.080.384.493.40.2170.568.968.566.374.70.110.033
MSP319.727.722.224.724.438.70.01117.111.919.012.621.40.00930.0003
MSP1111.118.912.016.426.725.80.00508.67.011.18.08.40.870.14
AMA188.496.695.795.997.897.90.3485.788.182.484.086.80.980.32
EBA-17578.288.788.083.695.690.30.3374.874.671.870.978.40.210.15
Pf4148.061.059.860.364.461.30.7543.841.844.940.046.20.400.64
  • a Information of the cutoff for positivity for each antigen is provided in Fig. S1 in the supplemental material. Significant P values (i.e., P < 0.05) are highlighted in bold. G, gravidity.

  • b Cochran-Armitage test: trend in binomial proportion of Ab+ cross level of gravidity.

  • c CMH, Cochran-Mantel-Haenszel test for the relationship between Ab+ and gravidity after controlling for malaria status.